Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.

View Full Paper
Ask AI
Bookmark
Share

Authors

BDBarbara DuplaixCGCamille GolfierSCStéphanie Cordeil

Discussion

Loading...

Member takes

Overview

Retrospective study reveals effective carfilzomib-based treatments in relapsed myeloma, suggesting favorable outcomes and tolerability.

Key Points

  • This research evaluates the safety and efficacy of carfilzomib-based combinations in patients with relapsed/refractory multiple myeloma.
  • Retrospective collection of demographic, safety, and efficacy data from multiple myeloma patients receiving carfilzomib-based treatments.
  • Response evaluation used IMWG criteria to assess progression-free survival and overall survival.
  • Univariate and multivariate analyses identified predictive factors influencing patient outcomes.
  • Data from 78 patients showed an overall response rate of 51% with a median progression-free survival of 6.7 months.
  • Patients had favorable toxicity profiles, with 23.5% reporting cardiovascular adverse events, predominantly hypertension.
  • The median overall survival was 16.6 months, demonstrating promising outcomes for carfilzomib-based therapies.

Cite This Study

Duplaix et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4eahttps://doi.org/10.1182/blood-2025-7530
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.2024
  2. 2Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study2024 · 5 citations
  3. 3Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026
  4. 4Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study2024 · 1 citations
  5. 5Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis2025